CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

CVM 1.95 -0.08 (-3.94%)
price chart
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, “Method of Preparation and Composition of Peptide Constructs for Treatment of ...
CEL-SCI Corporation Releases Letter to Shareholders
Our Phase 3 study in advanced primary (untreated) head and neck cancer patients with the investigational drug Multikine* (Leukocyte Interleukin Inj.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
Cel Sci Corporation (NYSEAMERICAN:CVM)'s Stock Is Buy After Less Market Selling
The stock decreased 5.12% or $0.11 during the last trading session, reaching $2.04. About 198,698 shares traded or 10.26% up from the average.
CEL-SCI Announces Adjustment to Warrant Exercise Price  Business Wire (press release)
CEL-SCI Co. (CVM) Short Interest Update  The Lincolnian Online
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
Analysts Layout Best- And Worst-Case Scenarios: CEL-SCI Corporation (CVM ...
CEL-SCI Corporation is maintained at an average hold rating by 1 stock analysts, and there are at least 4.82% of shares outstanding that are currently legally short sold.
CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate ...
CEL-SCI's LEAPS vaccine for the treatment of rheumatoid arthritis received a $1.5 million grant from the U.S. National Institutes of Health (NIH).
$0.52 EPS Expected for BofI Holding, Inc. (BOFI); Cel Sci (NYSEAMERICAN:CVM ...  Wolcott Daily
Tenet Healthcare Corp. (THC) is at $16.20 per share and CEL-SCI Corporation ...
In latest trading activity; Tenet Healthcare Corp. (THC) snatched the consideration from Investors, when its current damaging picture was seen that is promoting bad performance.
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...